Compare TERN & KBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TERN | KBR |
|---|---|---|
| Founded | 2017 | 1901 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 5.3B |
| IPO Year | 2021 | 2006 |
| Metric | TERN | KBR |
|---|---|---|
| Price | $47.62 | $36.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 8 |
| Target Price | $48.60 | ★ $53.14 |
| AVG Volume (30 Days) | ★ 1.8M | 1.3M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 1.81% |
| EPS Growth | 11.81 | ★ 15.05 |
| EPS | N/A | ★ 3.21 |
| Revenue | N/A | ★ $5,767,000,000.00 |
| Revenue This Year | N/A | $4.46 |
| Revenue Next Year | N/A | $5.21 |
| P/E Ratio | ★ N/A | $11.39 |
| Revenue Growth | N/A | ★ 2.27 |
| 52 Week Low | $1.87 | $36.33 |
| 52 Week High | $48.26 | $56.78 |
| Indicator | TERN | KBR |
|---|---|---|
| Relative Strength Index (RSI) | 70.28 | 30.28 |
| Support Level | $38.99 | N/A |
| Resistance Level | $48.26 | $43.85 |
| Average True Range (ATR) | 2.51 | 1.13 |
| MACD | 0.31 | -0.33 |
| Stochastic Oscillator | 97.42 | 3.50 |
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
KBR, formerly Kellogg Brown & Root, is a global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: mission technology solutions and sustainable technology solutions. KBR has operations in over 30 countries and employs approximately 34,000 people. The firm generated $7.7 billion in revenue in 2024.